Trial Profile
An open label, single-dose, five-way crossover study examining relative oral bioavailability of zanamivir with bioenhancing excipients following direct release into mid-small intestine using gamma scintigraphy and the InteliSite companion capsule in healthy subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Aug 2023
Price :
$35
*
At a glance
- Drugs Zanamivir (Primary)
- Indications Influenza virus infections
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 10 Jul 2007 New trial record.